Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway

Coronary Artery Disease

Volumn 9, Issue 2-3, 1998, Pages 83-87

  Johnson, Kirk ^a   Hung, David ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibodies; Coagulation; Factor VII; Inflammation; Nematode anticoagulant protein c2; Sepsis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; NEW DRUG; THROMBOPLASTIN;

BLOOD CLOTTING; INFLAMMATION; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0031862826     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809020-00004     Document Type: Review

References (75)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
2. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992, 29:159-169.
3. Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966, 5:601-608.
4. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977, 74: 5260-5264.
5. Osterud B. Tissue factor: a complex biological role. Thromb Haemost 1997 78:755-758.
6. Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988, 52:247-261.
7. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991, 33:127-134.
8. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehl P, Lowe D, et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997, 89:3219-3227.
9. Paborsky LR, Law VS, Mao CT, Leung LL, Gibbs CS. A peptide derived from a tissue factor loop region functions as a tissue factor-factor VIIa antagonist. Biochemistry 1995, 34:15328-15333.
10. Ronning HF, Risoen UC, Orning L, Sletten K, Sakariassen KS. Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex. Thromb Res 1996, 84:73-81.
11. Banner DW. The factor VIIa/tissue factor complex. Thromb Haemost 1997, 78:512-515.
12. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995, 73:223-230.
13. Taylor FB Jr. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 1996, 26 (suppl 1):83-91.
14. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996, 26 (suppl 1):76-82.
15. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995, 92:3041-3050.
16. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997. 25:341-346.
17. Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997, 272:11863-11868.
18. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995, 74:90-93.
19. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 1995, 74:7-17.
20. Sandset PM. Tissue factor pathway inhibitor (TFPI)-an update. Haemostasis 1996, 26 (suppl 4):154-165.
21. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997, 90:944-951.
22. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988, 263:6001-6004.
23. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988, 71:335-343.
24. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989, 338:518-520.
25. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992, 79:2004-2010.
26. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991, 78:394-400.
27. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995, 34:5725-5735.
28. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989, 264:18832-18837.
29. Gustafson ME, Junger KD, Wun TC, Foy BA, Diaz-Collier JA, Welsch DJ, et al. Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli. Protein Expr Purif 1994, 5:233-241.
30. Petersen JG, Meyn G, Rasmussen JS, Petersen J, Bjorn SE, Jonassen I, et al. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae. J Biol Chem 1993, 268:13344-13351.
31. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997, 78:471-477.
32. Dumanian GA, Heil BV, Khouri RK, Hong C, Labadie K, Wun TC, et al. Tissue factor and its inhibition at the human microvascular anastomosis. J Surg Res 1996, 60:263-269.
33. Lantieri LA, Ozbek MR, Deune EG, Ornberg RL, Brown DM, Chung SH, et al. Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor. Plast Reconstr Surg 1996, 97:587-594.
34. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993, 91:2850-2856.
35. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 1994, 44:126-137.
36. Camerota A, Creasey AA, Patla, V, Larkin V, Fink M. Delayed treatment with recombinant human tissue factor pathway inhibitor (TFPI) improves survival in rabbits with Gram-negative peritonitis. J Infect Dis 1998, 177:668-676.
37. Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 1993, 4:699-706.
38. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993, 91:2253-2259.
39. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997, 96:646-652.
40. Steinhubl SR, Belli G, Wu C, Yoon J, Furst J, Gallupi GR, et al. Local delivery of tissue factor pathway inhibitor (TFPI) to reduce neointimal proliferation in the porcine coronary balloon injury model. J Am Coll Cardiol 1997, 29 (suppl A): 243A.
41. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997, 78:1138-1141.
42. Erlich JH, Apostolopoulos J, Wun TC, Kretzmer KK, Holdsworth SR, Tipping PG. Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J Clin Invest 1996, 98:325-335.
43. Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996, 93:2149-2154.
44. Berkeley C, Rote W. Comparison of nematode anticoagulant proteins (NAPs) with low molecular weight heparin in a model of disseminated intravascular coagulation (DIC). Circulation 1996, 94 (suppl 8):I696.
45. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. J Biol Chem 1994, 269:22129-22136.
46. Refino C, Pater C, Wu D, Lazarus R, Dinnis M, Kelley R, et al. Evaluation of novel anticoagulants in a rabbit arterial thrombosis model. Blood 1995, 86 (suppl 1): 90a.
47. Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996, 76:5-8.
48. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995, 85:121-129.
49. Altieri DC. Xa receptor EPR-1. FASEB J 1995, 9:860-865.
50. ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997, 78:415-419.
51. Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992, 152:1381-1389.
52. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993, 9:1-26.
53. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984, 160:618-623.
54. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986, 83:4533-4537.
55. Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease. Thromb Diath Haemorrh 1971, 26:325-331.
56. Jansen PM, Pixley RA, Brouwer M, de Jong IW, Chang AC, Hack CE, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interteukin-6 and neutrophil elastase. Blood 1996, 87:2337-2344.
57. Wuillemin WA, Fijnvandraat K, Derkx BH, Peters M, Vreede W, ten Cate H. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995, 74:1436-1441.
58. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995, 270:4650-4660.
59. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995, 92:8205-8209.
60. Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDominicis G, et al. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 1997, 99:2446-2451.
61. Altieri DC. Proteases and protease receptors in modulation of leukocyte effector functions. J Leukoc Biol 1995, 58:120-127.
62. Piccardoni P, Johnson K, Altieri D. Factor Xa induction of a cytokine inflammatory response in vascular endothelim. Implication for a protease-activated signaling pathway. Proc Natl Acad Sci USA 1998, (in press).
63. Jones, A, Geczy CL Thrombin and factor Xa enhance the production of interleukin-1. Immunology 1990, 71:236.
64. Naldini A, Carney DH, Bocci V, Klimpel KD, Asuncion M, Soares LE, et al. Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 1993, 147:367-377.
65. Grandaliano G, Valente AJ, Abboud HE. A novel biologie activity of thrombin: stimulation of monocyte chemotactic protein production. J Exp Med 1994, 179:1737-1741.
66. Murakami K, Ueno A, Yamanouchi K, Kondo T. Thrombin induces GRO alpha/MGSA production in human umbilical vein endothelial cells. Thromb Res 1995, 79:387-394.
67. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells Mol Dis 1995, 21:156-167.
68. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW 2nd, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res 1996, 79:286-294.
69. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994, 144:975-985.
70. Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology 1996, 88:76-81.
71. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386:502-506.
72. Jansen PM, van Lopik T, Lubbers Y, de Jong IW, Brouwer M, Chang ACK, et al. Inflammatory mediators in Primate Sepsis. Academisch Proefschrift, University of Amsterdam, 1997.
73. Jansen PM, Pixley RA, Brouwer M, de Jong IW, Chang AC, Hack CE, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996, 87:2337-2344.
74. Johnson K, Aarden L, Choi Y, De Groot E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996, 87:5051-5060.
75. Park C, Creasey A, Wright, S. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997, 89:4268-4274.